Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 1, 2008, Pages 19-27

  Hiramatsu, Makoto ^a   Kubota, Minoru ^b   Iwasaki, Manabu ^c   Akizawa, Tadao ^d   Koshikawa, Shozo ^e   Nishitani, Takahiro ^f   Shoji, Takao ^g   Endo, Masayuki ^h   Numano, Masahiro ⁱ   Yamakawa, Tomoyuki ^j   Minakuchi, Jun ^k   Kawanishi, Hideki ^l   Hayashida, Shigeaki ^m   Hori, Kei ⁿ   Arizono, Kenji ^o   Yoshihara, Kunio ^p   Tsujimoto, Yoshihiro ^q  

^a OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^b Ouji Hospital   (Japan)

^c SEIKEI UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^f Obihiro Kosei General Hospital   (Japan)

^g YOKOSUKA KYOSAI HOSPITAL   (Japan)

^h TOKAI UNIVERSITY   (Japan)

ⁱ CITY GENERAL HOSPITAL   (United Kingdom)

^j Shirasagi Clinic

^k Kawashima Hospital

^l TSUCHIYA GENERAL HOSPITAL   (Japan)

^m Tokuyama Central Hospital

ⁿ Munakata Medical Association Hospital

^o KUMAMOTO CHUO HOSPITAL   (Japan)

^p Mamenoki Clinic   (Japan)

^q Inoue Hospital

more..

Author keywords

Anemia; Darbepoetin alfa; Peritoneal dialysis

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CATHETER INFECTION; CONTACT DERMATITIS; CONTROLLED STUDY; CONTUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 38849180940     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00525.x     Document Type: Article

References (21)

1. Desmond P, Liyun N, Blaire C et al. An extended terminal half-life for darbepoetin alfa. Clin Pharmacokinet 2006 45 : 503 10.
2. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999 10 : 2392 5.
3. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001 16 (Suppl. 3 3 13.
4. TM): a super-sialated erythropoietin with increased biological activity. Blood 2000 96 : 82A.
5. Egrie JC, Grant JR, Gillies KH et al. The role of carbohydrate on the biological activity of erythropoietin. Glycoconj J 1993 10 : 263.
6. Suranyi MG, Lindberg JS, Navarro J et al. Treatment of an* with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003 23 : 106 11.
7. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hb) in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol 1999 10 : 270A.
8. Mahajan S, Boulton H, Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004 17 : 678 92.
9. Brunkhorst R, Bommer J, Braun J, Haag-Weber M et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004 19 : 1224 30.
10. Mahajan S, Boulton H, Gokal R. A trail of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004 17 : 687 92.
11. Vanrenterghem Y, Barany P, Mann FEJ et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002 62 : 2167 75.
12. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001 60 : 741 7.
13. Toto DR, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004 24 : 453 60.
14. Jadoul M, Vanrenterghem Y, Foret M et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004 19 : 898 903.
15. Ling B, Walczyk M, Agarwal A. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005 63 : 327 34.
16. Theodoridis M, Passadakis P, Kriki P et al. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int 2005 25 : 564 9.
17. Gejyo F, Saito A, Akizawa T, et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004 8 : 443 59.
18. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006 10 : 476 97.
19. Onuma H, Tsutsumi K, Matsumoto A et al. Administration of erythropoietin gives the large burden to the peritoneal dialysis patients' going to hospital regularly. Clin Dial 2004 20 : 1707 12.
20. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 19 (Suppl. 2 ii1 47.
21. Eknoyan G, Levin NW, Eschbach JW et al. Continuous quality improvement: DOQI becomes K/DOQI and is updated. Am J Kidney Dis 2001 37 : 179 94.